A novel horticultural approach that delivers long-lasting disease resistance in tomato plants by treating rootstocks with priming agents, bypassing the fitness costs typically associated with direct plant treatment. This grafting-based strategy enables commercial varieties to inherit pathogen resistance without yield penalties.
This research proposes an innovative strategy to deliver long-lasting induced resistance in tomato crops by exploiting the natural graft junction between rootstock and scion. Priming agents (PAs) such as β-amino butyric acid (BABA) are powerful tools that activate defence mechanisms against pests and pathogens, but their commercial use has been limited by associated fitness costs, including reduced growth and yield. Preliminary evidence suggests that while these negative effects are temporary, the induced resistance is stably maintained through the plant's life, expressed in newly developed tissues, and even inherited by the next generation. By applying PAs only to rootstocks, which fully recover from any growth reduction before grafting, the long-lasting resistance can be transmitted to untreated scions, providing an efficient and economic disease management solution for commercial horticulture.
Key features:
Validation approach:
This technology is at an early-to-mid stage of development. The underlying biological mechanism has been established through omics-based research demonstrating that BABA-induced DNA methylation changes separate resistance traits from fitness costs. The core concept, that long-lasting resistance is transmissible through grafting while growth penalties are not, is supported by preliminary data but has not yet been validated in grafted plants. Current work involves testing BABA-treated rootstocks paired with naive scions across model and commercial tomato cultivars. Further validation is needed to confirm resistance transmission, quantify effects on yield and fruit quality, and identify the genetic loci responsible before commercial deployment can be considered.
The University of Birmingham is a comprehensive public research university of significant scale in the UK’s second city. For industry, a campus‑adjacent research park provides office and wet‑lab space, including the BioHub biomedical incubator managed by University of Birmingham Enterprise. Clinical collaboration is enabled through Birmingham Health Partners, aligning the university with NHS hospital trusts for translational studies and access to patient pathways. Energy and sustainability ventures tap the Birmingham Energy Innovation Centre and wider facilities at Tyseley Energy Park, creating a proving ground for low‑carbon technologies and scale‑up. Research is backed by competitive UK funding, including UKRI councils, Innovate UK, and NIHR, and a dedicated tech transfer office manages IP, licensing, and spinouts to speed corporate partnerships.